Top Biotech Stock Pick From TD Cowen: Agios Leads on Thalassemia Strength

TD Cowen reiterated Agios as its top biotech pick after new EHA 2026 data reinforced mitapivat’s profile across thalassemia, sickle cell disease, and polycythemia vera. In Phase 3 RISE-UP, hemoglobin improved 0.77 g/dL versus 0.03 g/dL on placebo, while transfusions fell 41% and RBC units transfused per patient fell 56%. The Aqvesme launch is running ahead of expectations with about 242 prescriptions by quarter-end, implying roughly $82M annualized demand versus $63M FY2026 consensus.

Analysis

The market is likely still underestimating how much of AGIO’s re-rating can come from non-consensus durability rather than just headline launch beats. If mitapivat continues to show improving response curves in thalassemia and sickle cell, the stock can start trading like a multi-asset franchise with longer terminal value, not a single-product launch story; that typically expands the multiple before earnings fully catch up. The biggest second-order winner is likely the company’s commercial leverage: every incremental share gain in the current launch should flow disproportionately to valuation because the market has been pricing a more binary clinical readout profile than is warranted.

The key risk is that the current setup becomes crowded into the next catalyst window, making the stock vulnerable to a "good but not enough" reaction if confirmatory data are merely adequate rather than clearly superior. The timeline matters: near-term sentiment can stay strong for days to weeks, but the next 3-6 months will be dominated by whether launch momentum sustains and whether the confirmatory trial retains the same magnitude of effect on a stricter endpoint. A failure mode would be trial heterogeneity across hemoglobinopathies, which could compress expectations for the broader franchise even if one indication remains intact.

The underappreciated angle is competitive dynamics in the rare hematology basket. A stronger AGIO launch can pull capital away from slower-growing orphan names and force a relative-value reset across the sub-sector, especially for companies still at the proof-of-concept stage. On the pipeline side, the TMPRSS6 program introduces a longer-dated optionality layer that the market may be discounting too heavily because it is not yet a near-term revenue driver; if that data matures, AGIO becomes less dependent on a single commercial narrative.

Key Decisions for Investors

• Long AGIO into the next 1-3 month catalyst window; use pullbacks rather than strength to enter, with a 15-20% upside target if launch momentum continues and the market re-rates the commercial durability story.
• Buy AGIO call spreads 3-6 months out to express upside while capping premium outlay; favorable if you expect estimate revisions but want defined risk around a 'good-not-great' data reaction.
• Pair trade: long AGIO / short a basket of slower-moving orphan/rare-disease names with weaker launch visibility over the next 2 quarters; thesis is relative multiple expansion for AGIO as commercialization risk compresses.
• If already long, reduce exposure 25-30% into any sharp post-data gap higher; the main risk is multiple compression once the market front-runs the next confirmatory readout.
• Monitor confirmatory trial and launch cadence as a 6-month check: if prescriptions and response durability remain on trend, add on breaks; if launch momentum stalls, reassess quickly because the stock likely trades on execution confidence more than distant pipeline value.